A Radical Proposal to Preserve Cell and Gene Therapy Innovation
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to…
A Radical Proposal to Preserve Cell and Gene Therapy Innovation
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail. The post A Radical Proposal to Preserve Cell and Gene Therapy Innovation appeared first on MedCity News.
KFF Tracking Poll on Health Information and Trust: Fall 2026 Update on Vaccine Views
The latest KFF Tracking Poll on Health Information and Trust finds about half of parents mistakenly believe spacing out vaccines is healthier for children, while confidence in many long-standing childhood vaccines is high across partisans. These findings take on new relevance following President Trump’s recent executive order calling for changes in U.S. childhood vaccine recommendations,…
Report: Health System M&A Activity Remains Steady in Third Quarter
A new report on third quarter M&A activity in the healthcare sector found that this quarter’s hospital and health system transactions remained steady, with 2026 potentially set to be a top year for total annual transactions since pre-pandemic times. The post Report: Health System M&A Activity Remains Steady in Third Quarter appeared first on MedCity…
Democrats Demand Tougher Standards for Companies Running Medicaid Systems
A group of Democratic senators is demanding that the federal agency overseeing Medicaid — the health coverage program for people with low incomes or disabilities — institute tougher standards for government contractors running complex computer systems that millions of people rely on to get benefits. Three Democratic senators issued recommendations a year after launching an…
As Politicians Argue About China, US Patients Find Cutting-Edge Treatment There
Until recently, a Manhattanite might venture no more than a few dozen blocks to find the world’s most sophisticated cancer treatment. Cutting-edge American medicines have helped reduce the U.S. cancer death rate by about a third since 1990, and New York City hospitals deliver some of the best care in the country. But in January…
More Medications, More Risks. If You’re Worried, Start a Deprescribing Discussion.
(Maria Fabrizio for WPLN and KFF Health News) For nearly three years, Jonathan Bledsoe of Reading, Pennsylvania, took one prescription to stabilize his mood and one to keep his cholesterol in check, among a handful of other medications. “You wouldn’t think you would have to be your own advocate and look out for yourself as…
Building the AI Hospital
Walk into the emergency room at Israel’s largest hospital and the first clinician to take your history may be an AI avatar — with a physician signing off on every recommendation. Israel’s Sheba Medical Center is building what could become the first fully AI-based hospital by 2030. Dr. Eyal Zimlichman, Sheba’s Chief Transformation Officer, Chief…
Big Bucks, No Whammies, Part 2: So You Won. Now What?
By STEPHEN FARBER Part one argued that patient access was never the finish line; it was the foundation. This is about what we build now that we are standing on it. Every good game show has a second round, and the second round is always harder. The first round was about getting health information out…
AdvaMed’s 4 Policy Priorities, According to Its CEO
AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity. The post AdvaMed’s 4 Policy Priorities, According to Its CEO appeared first on MedCity News.
Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer
The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and a potential dosing advantage over a Takeda Pharmaceutical product recently approved in this indication. The post Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare…
